To counter your smart-a$$ response to @Trade4Profit88 , yes, I think we will definitely need all the luck in the world with this. Any thoughts on the below?
Company QEM Ltd Vanadium Resources Australian Vanadium Ticker QEM VR8 AVL Projects Julia Creek, QLD Steelpoortdrift, SA Meekatharra, WA Ownership 100% 74% 100% LOM ? 40 25 MRE (MT) 2850 662 239 Grade (%V2O5) 0.31% 0.77% 0.73% V 2O5(KT) Resource 8,835 5,097 1,745 Reserve ? 560 337 Fe (KT) Resource Reserve 22875 Ti 2O3 (KT) Resource Reserve Nameplate Capacity (Ktpa) 12500 11,200 NPV8 (Post Tax)(AUD) $- $1,183,200,000 $666,400,000 C1 Cost (AUD/lb) V2O5 $- $4.11 $5.91 EBITDA $- $227,766,000 $175,000,000 CAPEX $- $266,666,667 $604,000,000 NPV8/Share $- $2.501 $0.168 EBITDA/Share $- $0.481 $0.044 Capital Intensity n/a $1.171 $3.451 SOI 113,423,333 473,112,374 3,963,962,598 Share price $0.210 $0.080 $0.043 Market Cap $23,818,900 $37,848,990 $170,450,392 Mkt-Cap/NPV n/a 3.20% 25.58% Top 20 Ownership (%) 67.0% 62.8% 25% Management Buy-In (%) 46% 11% ? Status PFS in-progress DFS in-progress, due Sep'22 BFS complete, Targeting FID in Q4 2022 Notes:
(1) AVL: Pre-tax NPV7.5 of A$833M and equity IRR 20.6% based on US$10.50/lb V2O5 price, while VR8 post-tax NPV8 based on US$9.30/lb V2O5 long term price. What this means is that VR8's post-tax NPV, at a higher WACC, is about twice your pre-tax NPV at a lower WACC. Hmmm...
(2) AVL: C1 costing includes by-product revenue from Iron oxide by-product. VR8 C1 cost is based on V2O5 pure-play. I don't think I need explain this one.
- Forums
- ASX - By Stock
- what is Avl worth ?
AVL
australian vanadium limited
Add to My Watchlist
5.56%
!
0.9¢

To counter your smart-a$$ response to @Trade4Profit88 , yes, I...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.9¢ |
Change
-0.001(5.56%) |
Mkt cap ! $73.39M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.8¢ | $16.42K | 1.960M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 15131891 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 11584158 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
45 | 15599284 | 0.008 |
29 | 10474770 | 0.007 |
13 | 14668333 | 0.006 |
10 | 7588888 | 0.005 |
8 | 20780000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 11676666 | 29 |
0.010 | 18390233 | 40 |
0.011 | 5987537 | 22 |
0.012 | 6679018 | 19 |
0.013 | 3738838 | 18 |
Last trade - 12.36pm 27/06/2025 (20 minute delay) ? |
Featured News
AVL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online